The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests.

Jefferies sees Arbutus (ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK ...

The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a ...

Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and ...

Vaccine stocks and EV maker Lucid Technologies (LCID) are among today’s biggest winners today. Vaccine makers, including ...

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

RNA is a long, polymeric molecule, composed of four different building blocks called nucleotides. In the last decade mRNA has progressed into a promising new class of medicine, with the potential to ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

The university filed a lawsuit against BioNTech four months ago, claiming that the company licensed vaccine technology ...